Although many quality measures have been created, there is no consensus regarding which are the most important. We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population.
Using performance data for 9019 breast cancer patients treated at 10 National Comprehensive Cancer Network institutions, we assessed concordance relative to 30 reliable, valid breast cancer process-based treatment measures. We identified 4 attributes that indicated there was room for improvement and characterized the extent of burden imposed by failing to follow each measure: number of nonconcordant patients, concordance across all institutions, highest concordance at any 1 institution, and magnitude of benefit associated with concordant care. For each measure, we used data from the concordance analyses to derive the first 3 attributes and surveyed expert breast cancer physicians to estimate the fourth. A simple algorithm incorporated these attributes and produced a final score for each measure; these scores were used to rank the measures.
We successfully prioritized quality measures using explicit, objective methods and actual performance data. The number of nonconcordant patients had the greatest influence on the rankings. The highest-ranking measures recommended chemotherapy and hormone therapy for hormone-receptor positive tumors and radiation therapy after breast-conserving surgery.
This simple, explicit approach is a significant departure from methods used previously, and effectively identifies breast cancer quality measures that have broad clinical relevance. Systematically prioritizing quality measures could increase the efficiency and efficacy of quality improvement efforts and substantially improve outcomes.
From the *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; †Division of Information Sciences, City of Hope National Medical Center, Duarte, California; ‡Department of Breast and Soft Tissue Surgery, Roswell Park Cancer Institute, Buffalo, New York; §Fox Chase Cancer Center, Philadelphia, Pennsylvania; ¶Stanford Hospital and Clinics, Stanford Cancer Center, Stanford, California; and ∥University of Texas MD Anderson Cancer Center, Houston, Texas.
This work was supported in part by a Grant P50 CA89393 from the National Cancer Institute to Dana-Farber Cancer Institute.
M. J. H. received salary support from R25 CA092203. The sponsors had no direct influence on the design of the study, analysis of the data, interpretation of the results, or writing of the manuscript.
Presented at the 2006 Academy Health Annual Research Meeting, June 25–27, 2006, Seattle, WA.
Reprints: Michael J. Hassett, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. E-mail: firstname.lastname@example.org or email@example.com.